San Mateo, Calif., United States: Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLLTwo oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673Oral presentation highlights continued deep and durable responses and manageable tolerability observed in Phase 1 …
